Form D · Biotechnology

AOA DX Inc.

Denver, CO · CIK 0001869920

Offering snapshot reported Oct 15, 2025 · SEC filing

Reported sold
$8.09M
Offering amount: $30.6M
Investors reported
40
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 1, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 15, 2025Initial$8,085,364No comparison40SEC filing
Dec 19, 2024Initial$1,845,060No comparison15SEC filing
Jul 26, 2023Initial$23,611,721No comparison119SEC filing
Nov 18, 2021Initial$2,639,450No comparison33SEC filing
Jul 7, 2021Initial$2,500,000No comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-560927
Amounts include securities issued upon conversion of outstanding promissory notes and warrants authorized for issuance in connection with the offering.

Source: Form D, filed Oct 15, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Alexander James Fisher Executive
John Friedman Director
Anna Milik Jeter Executive
Abigail Mcelhinny Executive
Anna Milik Jeter Director, Executive
Oriana Papin Zoghbi Director, Executive
Surbhi Sarna Director
Oriana Zoghbi Harb Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
6860 Broadway Unit B
Denver, CO, 80221